JCR.F JCR Pharmaceuticals Co., Ltd.

Healthcare Drug Manufacturers - General Frankfurt Exchange
2.74 EUR
Close of Nov 12, 2026
2.31 4.06
Market cap
EUR 334M
P/E
-
P/B
1.48x
ROE
-17.7%
Dividend yield
4.03%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is JCR.F undervalued?

Graham number

The Graham number of JCR Pharmaceuticals Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

JCR Pharmaceuticals Co., Ltd. fundamental analysis

No fundamental analysis for JCR Pharmaceuticals Co., Ltd. yet.

JCR Pharmaceuticals Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusi…

Full company profile